Review Article | Open Access
Teng Ma, Meng-Shan Tan, Jin-Tai Yu, Lan Tan, "Resveratrol as a Therapeutic Agent for Alzheimer’s Disease", BioMed Research International, vol. 2014, Article ID 350516, 13 pages, 2014. https://doi.org/10.1155/2014/350516
Resveratrol as a Therapeutic Agent for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, but there is no effective therapy till now. The pathogenic mechanisms of AD are considerably complex, including Aβ accumulation, tau protein phosphorylation, oxidative stress, and inflammation. Exactly, resveratrol, a polyphenol in red wine and many plants, is indicated to show the neuroprotective effect on mechanisms mostly above. Recent years, there are numerous researches about resveratrol acting on AD in many models, both in vitro and in vivo. However, the effects of resveratrol are limited by its pool bioavailability; therefore researchers have been trying a variety of methods to improve the efficiency. This review summarizes the recent studies in cell cultures and animal models, mainly discusses the molecular mechanisms of the neuroprotective effects of resveratrol, and thus investigates the therapeutic potential in AD.
AD is a progressive, degenerative disorder and by far the most common cause of dementia. The pathogenesis and progression of AD are not well understood; however, the characteristic histopathologic features are studied extensively, including neuritic plaques (senile plaques), neurofibrillary tangles, loss of neurons and synaptic connections, and glial proliferations . Although the detailed causes of AD are still in debates, two pathological hallmarks have been widely identified: senile plaques (SPs) and neurofibrillary tangles (NFTs). SPs consist of deposits of β-amyloid protein (Aβ) as a core which is surrounded by dystrophic neuritis, activated astrocytes, and microglia. The NTFs are formed by hyperphosphorylation and abnormal deposition of tau proteins . Scientists have been trying for a long time to treat and to alleviate the cognitive impairment. Unfortunately, no currently available treatment has been shown to reverse existing deficits or to prevent disease progression .
Many pharmacotherapies have been applied clinically to ameliorate the symptoms of AD, such as several cholinesterase inhibitors and memantine, an N-methyl-D-aspartate- (NMDA-) type glutamate receptor antagonist drug. However, these drugs have been shown to produce diverse side effects and yield relatively modest benefits, by reason of the complex mechanisms . For example, cholinesterase inhibitors present only temporary and modest effects on improvement of memory impairment and motor function, but the side effects tend to be intolerable, such as nausea and diarrhea. Tacrine, another cholinesterase inhibitor, has been limited in clinical treatment because of the poor oral bioavailability and severe hepatotoxicity. Memantine, which used to be a hopeful drug, has proved to be less effective clinically than the cholinesterase inhibitors . Therefore, there is an urgent need for new strategies based on multiple pathomechanisms of AD.
Resveratrol (3, 5, 4′-trihydroxy-trans-stilbene) is a kind of polyphenol produced in several plants, especially grapes skin and seeds, and a phytoalexin against pathogens such as bacteria or fungi . An epidemiological research was reported between moderate red wine consumption and a low incidence of cardiovascular disease, which was termed “French Paradox” . Afterwards the studies indicated that resveratrol showed the diverse biological activities, such as antioxidant, anti-inflammatory, phytoestrogenic, vasorelaxing, cardioprotective, and anticarcinogenic, which help it to play important roles in treatment against cardiovascular diseases and cancers, as well as degenerative disorders in brain, including AD [8–10]. Numerous researches have been carried out to find whether resveratrol can take a therapeutic potential in AD and other neurodegenerative diseases, including various models in vitro and in vivo. Although the researches on resveratrol and AD are still in the infancy and the long-term effects of clinical supplementation in human are not known, more and more studies have indicated that resveratrol was involved in several pathophysiologic courses of AD . In this review, we searched the MEDLINE, EMBASE, CINAHL, and BIOSIS previews up to January, 2014, with the terms “resveratrol” or “trans-resveratrol” or “RES” or “RSV” and “Alzheimer’s disease” or “Alzheimer disease” or “AD.” The search terms were used to identify relevant therapeutic effects of resveratrol on AD, both in vitro and in vivo, as well as clinical trials. On the whole, 97 publications were included in the full-text screening. We also enumerate the roles of resveratrol in AD pathogenesis and in AD therapy and discuss the benefit of resveratrol as a therapeutic agent of AD.
2. Complex Pathogenesis and Multiple Targets for Treatment
The pathogenic mechanisms of AD are considerably complex (Figure 1), so that most of the treatments are unable to take every aspect into account. AD is defined by characteristic pathologic features, especially neuritic plaques and NFTs, which are clearly visible by microscopy in brains of those afflicted by AD . Neuritic plaques, also called senile plaques, are extracellular insoluble deposits of Aβ peptide. In 1992, the amyloid hypothesis postulated that Aβ deposits were the elementary cause of AD and since then the hypothesis had been gradually acknowledged . Amyloid precursor protein (APP) is abnormally cleaved by β- and γ-secretases, but not α-secretase, which leads to excessive extracellular accumulation of Aβ in the cortex and hippocampus in AD brains. Aβ accumulation leads to the progressive loss of neurons, interdict of neural circuits, and neurological decline characteristic of AD . However, APP will be cleaved into soluble amyloid precursor α (sAPPα) by α-secretase pathway, which can relatively reduce the generation of Aβ and protect neurons by promoting axon growth. Therefore, β- and γ-secretases are considered to be the pivotal targets of AD pharmaceuticals, but on the contrary enhancement of α-secretase may produce the similar effect in anti-AD treatment.
Oxidative stress has been strongly involved in the pathogenesis of neurodegenerative diseases including AD. The brain tends to be very prone to oxidative imbalance and vulnerable to oxidative damage, due to the higher levels of polyunsaturated fatty acids and the relative lack of antioxidant systems, compared with other organs [5, 14]. It is regarded as an underlying cause of AD because of the reactive oxygen species (ROS) and reactive nitrogen species during the early development of the disease, preceding the formation of senile plaques . A large number of ROS are produced by damaged mitochondria during oxidative stress, mainly including inducing nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and these productions may damage the mitochondrial and cellular proteins and nucleic acids, causing lipid peroxidation and resulting in the loss of membrane integrity . ROS increasing Aβ production and Aβ inducing oxidative stress, a vicious circle between ROS and Aβ accumulation, may accelerate the progression of AD . Thus, antioxidants have been demonstrated to protect against Aβ-induced neurotoxicity . Resveratrol, as an antioxidant, is found to reduce iNOS levels and alleviate lipid peroxidation in neuron cells and, however, increase the production of heme oxygenase-1 (HO-1) to attenuate oxidative damage.
Recent evidences suggest that neuroinflammation is an important contributor to pathogenesis of AD. Inflammatory changes, including the activation of microglia, astrocytes, and macrophages, are observed in the AD brain, particularly in the amyloid deposits . Numerous evidences in cell cultures and mouse models indicate that aggregated Aβ is responsible for the activation of astrocytes and microglia , causing the release of large amounts of proinflammatory mediators, including cytokines, free radicals, and nitric oxide (NO), all of which increase the generation of insoluble Aβ [18, 19]. Aβ triggers the respiratory burst of microglia and produces ROS and tumor necrosis factor alpha (TNF-α), which aggravates Aβ deposition and further neuronal dysfunction and eventual death . The potentially significant contribution of inflammatory mechanisms in AD has prompted consideration of anti-inflammatory treatment strategies .
Tau protein is a highly soluble microtubule-associated protein (MAP). These proteins mostly exist in neurons, both central and peripheral nervous systems, and perform the function of stabilizing microtubules . Tau is a phosphoprotein and the phosphorylation of tau is regulated by many kinases. When the tau protein is phosphorylated, it deviates from microtubules and aggregates abnormally, which is known as tauopathies, including AD . The phosphorylated tau protein results in the disassembling of microtubules and aggregates to form neurofibrillary tangles, a hallmark of AD pathology. Once polymerized into neurofibrillary tangles, the tau loses the function of connection to tubulin and microtubule assembly. Thus, inhibition of pathological hyperphosphorylation of tau may be a therapeutic target for AD and other tauopathies [23, 24].
Neuron-synapse loss was considered as one of the main features of AD and other neurodegenerative disorders and possibly the direct cause of dementia occurrence and deterioration [25, 26]. Synaptic dysfunction is found in the early phase of AD, and loss of synapses appears in the later phase. As a result, the excitatory transmission in hippocampus and cerebral cortex is inhibited, which contributes to memory loss [27, 28]. Although Aβ deposition may cause neuron loss, the main way of neuron-synapse loss is apoptosis. In AD models, there are various factors which can launch the apoptosis, such as oxidative stress, glucose metabolism disorder, and excitotoxic mitochondrial damage. In addition, some substrates, for example, p53, FOXO, and ROS, are involved in the apoptosis process of AD. Thus, downregulation of apoptosis seems to be a potential treatment of AD.
The treatments of many progressive neurodegenerative maladies, such as Huntington’s disease, Parkinson’s disease, and AD, have been the puzzles in neurology. Resveratrol is known to have beneficial metabolic effects and is considered a mimic of caloric restriction . In recent years, resveratrol has been shown to have neuroprotective effects for its pleiotropic functions. Researches indicate that resveratrol may promote clearance of Aβ, mitigate oxidative stress, decrease the production of proinflammatory factors, scavenge free radicals, inhibit platelet aggregation, suppress activation of astrocytes and microglia, and reduce neuron cell death . In all, studies show that resveratrol possesses potent neuroprotective properties in several models, both in vitro and in vivo.
3. Neuroprotective Effects of Resveratrol In Vivo
Resveratrol has been found to exhibit neuroprotective function in animal models, mostly rat models (Table 1). It is reported that daily moderate consumption of the red wine Cabernet Sauvignon significantly reduced AD-type amyloid neuropathology and attenuated Aβ-associated spatial memory deterioration in the Tg2576 mouse model. However, the role of resveratrol in this study was not clear because the content of resveratrol in Cabernet Sauvignon was much lower than the minimal effective concentration shown to promote Aβ clearance in vitro . Recent studies about Tg2576 mice indicated that extracellular accumulation of soluble Aβ oligomers was largely responsible for AD dementia and memory deficits . Grape seed polyphenolic extract (GPSE) treatment reduced oligomerization of Aβ peptide and attenuated amyloid-associated cognitive impairments in Tg2576 mice . In resveratrol-treated APP/PS1 mice, there was a significant reduction in the number of activated microglia, suggesting that resveratrol decreased inflammation, at least in part, independently of its effect on amyloid deposition .
In male C67BL/6J mice, resveratrol reduced serum TNF-α and macrophage infiltration of adipose tissue, attenuated neuroinflammation and oxidative stress in the hippocampus, and enhances cognitive function in HFD-fed mice . In another study on male C57Bl/6 mice, resveratrol was provided in the food (150 μg resveratrol/gram food). As a result, resveratrol-treated mice were improved in spatial orientation and memory performance, which was paralleled by an increased microvascular density in the hippocampus and decreased number of vacuolar abnormalities in both hippocampal and cortical microvascular endothelial cells . Moreover, in C57Bl/6J mice model, research showed that in resveratrol-treated high fat-fed mice, there was a significant decrease in ambulatory locomotor activity as well as a tendency to decrease the number of rears. The data demonstrated that the effects of resveratrol were seen in both muscle and brown adipose tissue, and this might result in an increase in mitochondrial function, which translated into an increase in energy expenditure, an improved aerobic capacity, and an enhanced sensorimotor function .
To extend their in vitro results, Dasgupta and Milbrandt conducted an experiment and found that intraperitoneal injection of resveratrol acutely activated AMP-activated kinase (AMPK) in the brain, probably due to the phosphorylation and inhibition of acetyl-CoA carboxylase (ACC) . Streptozotocin is usually used to build diabetes rat models, which may show up impairment of memory. In intracerebroventricular (ICV) injection of streptozotocin (STZ) model rats, there could be impairment in learning and memory in addition to decreased choline acetyltransferase levels in the hippocampus, because of the prolonged impairment of brain glucose and energy metabolism. Sharma and Gupta indicated that ICV STZ group rats chronically treated with trans-resveratrol showed significantly increased retention latencies and shorter transfer latencies on the elevated plus maze, but no significant difference in the locomotor activity of sham . Other rat models were made by ICV administration of colchicine (15 μg/5 μL), which could induce impaired cognitive functions. Chronically treated with resveratrol for 25 days, the malondialdehyde (MDA) and nitrite levels reduced, the glutathione and acetylcholinesterase activity recovered, and the cognitive impairment induced by colchicine was greatly improved .
In the adult male Wistar rats with intraperitoneal injection of 55 mg/kg streptozotocin, treatment with resveratrol significantly prevented the increase in AChE activity, especially in the cerebral cortex and hippocampus. In addition, treatment with resveratrol was able to prevent the increase in AChE activity and consequently in cognitive impairment in diabetic rats, which meant that this polyphenol could modulate cholinergic neurotransmission and consequently improve cognition . Furthermore, another study showed oral resveratrol induced the expression of brain derived neurotrophic factor (BDNF) mRNA in the hippocampus of rat brain in the male Sprague-Dawley rat models. BDNF had several neuroprotective roles similar to those of resveratrol and the study indicated resveratrol might have positive effects on the expression of BDNF .
The silent information regulator 2 (SIR2) gene promotes longevity in a variety of organisms and may underlie the health benefits of caloric restriction. SIRT1, one of the seven mammalian homologues of the sirtuin family of NAD+-dependent deacetylases, has recently been demonstrated to contribute to cellular regulation and take part in several signal transduction pathways . It is found that resveratrol possesses the ability to activate SIRT1, although there is a viewpoint that resveratrol is not a direct activator . In the inducible p25 transgenic mouse, a model of AD and tauopathies, ICV injection of resveratrol resulted in the activation of SIRT1. After 5 weeks of p25 induction, cell death and neurodegeneration were obvious in the hippocampus of the vehicle treated animals, but administration of resveratrol could reduce neurodegeneration in CA1 and CA3 regions of the hippocampus because of the lower levels of the apoptotic marker-activated caspase-3 and glial fibrillary acidic protein (GFAP), a marker of astrogliosis. p25-green fluorescent protein (GFP) expressing neurons were more robust in the hippocampus of resveratrol-treated rats, demonstrating the neurons might tolerate and survive p25 expression. Learning capability improved after treatment with resveratrol for 3 weeks. That is to say resveratrol provides neuroprotection and prevents cognitive decline in animal models .
Therefore, resveratrol is beneficial for animal neurodegenerative disorders induced by some neurotoxicity. The possible mechanisms may be responsible for its antioxidant and anti-inflammatory properties. Pretreatment with resveratrol significantly attenuates oxidative stress damage and improves motor and cognitive impairment [58, 59].
4. Neuroprotective Functions of Resveratrol In Vitro
The neuroprotective effects of resveratrol have been investigated in several in vitro models, either rat cells or human cells (Table 2). In hippocampal slices prepared from 10-day-old Sprague-Dawley rat pups, glutamate rapidly induced monocyte chemotactic protein-1 (MCP-1) production in the hippocampus. Resveratrol downregulated glutamate-induced extracellular signal-regulated kinase (ERK) activation and then resulted in decreased interleukin-1β (IL-1β) expression and the subsequent downregulation of MCP-1 in the hippocampus . In the rat cortical primary neurons, a decrease in peroxisome proliferator-activated receptor-gamma coactivator- (PGC-) 1α was observed, suggesting that SIRT1 activity was increased following resveratrol treatment of primary neurons. Furthermore, increased levels of SIRT1 in primary neurons played protective roles against neurotoxicity induced by p25 or mutant SOD1. Resveratrol provided neuroprotection and prevented cognitive decline through the deacetylation of p53 and the sequent decreasing of p53 level, an important mediator of cell death . A study on primary cortical neuron cultures showed that resveratrol was effective in protecting against NMDA-induced neuronal death by inhibiting the elevation of intracellular calcium and production of ROS . In a study on primary hippocampal cultured cells, Aβ25–35 was used to establish Aβ-induced neuronal cell death, because of its similar mechanism of toxic effect. A pretreatment of hippocampal neuronal cells with resveratrol (15–40 μM) significantly reduced Aβ25–35-induced cell death in a dose-dependent manner, with a maximal effect obtained at 25 μM. Meanwhile, cotreatment and posttreatment with resveratrol showed similar neuroprotective effects, although the effects seemed to be with a somewhat lower potency. The phosphorylation of protein kinase C (PKC) was induced by resveratrol in a dose-dependent manner, with maximal effects seen at 20–30 μM. Moreover, resveratrol slightly decreased the phosphorylation of PKC-d, but did not affect the phosphorylation of PKC-α/βII, PKC-μ (Ser916), and PKC-θ (Thr538), suggesting that PKC-δ (Thr505) was involved in the neuroprotective effects of resveratrol. In short, the PKC pathway played a major role in the neuroprotective-neurorescuing properties of resveratrol against Aβ-induced toxicity in hippocampal neurons . In mixed (glial/neuronal) hippocampal cultured cells, treatment with the NO donor SNP (100 μM) resulted in cell damage and resveratrol (5 ± 25 μM) treatment increases cell survival, and this protective effect was significant at 5 μM and maximal at the highest (25 μM) concentration tested. Thereby, resveratrol, as well as other red wine polyphenols, was able to rescue hippocampal cells against toxicity induced by NO, possibly mediated by antioxidant activities. Interestingly, in this experiment resveratrol and catechin, but not quercetin, did not involve inhibitory effects on intracellular enzymes such as COX/LOX, NOS, and PKC. However, other researches found that resveratrol (10 μM) inhibited NO generation and suppressed iNOS in lipopolysaccharide- (LPS-) activated macrophages. The contradiction may be due to different experimental conditions, including cell types and toxic agents . Resveratrol can also inhibit prostaglandin E2 (PGE2) and free radical formation by activated microglial cells in primary cultured microglial cells, because of the modulation of multiple events in the COX/PGE2 pathway. Resveratrol can reduce LPS-mediated expression of microsomal prostaglandin E synthase-1 (mPGES-1) and COX-1, but not COX-2 expression . In cultured rat astroglioma C6 cells, Aβ induced a time-dependent reduction of cell growth, but pretreatment with resveratrol protected the cells from the toxicity of Aβ. In this research, resveratrol inhibited NO production and iNOS expression in response to Aβ in a concentration-dependent manner. Furthermore, resveratrol showed the inhibitory effects on the accumulation of PGE2 by Aβ through downregulation of COX-2 in C6 cells. In addition, pretreatment with resveratrol prevented the translocation of NF-κB by Aβ .
A recent study was executed on murine macrophage cell line RAW 264.7, murine microglial cell line BV-2, and murine bone marrow-derived pro-B cell line Ba/F3. It was found that resveratrol treatment significantly reduced multiple cytokines in LPS-stimulated RAW 264.7 and BV-2 cells, such as IL-6, M-CSF, CD54, IL-1ra, and TNF-α, which were all transcriptionally controlled by NF-κB. NF-κB signaling controls the expression of iNOS and cathespin B, which are the known toxic factors involved in apoptosis. Resveratrol decreased the levels of phosphorylated IKKα, IκBα, and NF-κB in RAW 264.7 and BV-2 cells and even greatly inhibited the phosphorylation of Akt, a kinase controlled by MyD88 upon Toll-like receptor (TLR) 4 activation. On the other hand, resveratrol also inhibited signal transducer and activator of transcription (STAT) 1 and STAT3 activation by LPS in these two cell lines and reduced the expression of iNOS and COX-2 in a dose-dependent manner. Resveratrol treatment significantly lowered the levels of FLAG-tagged TLR4 coimmunoprecipitating with GFP-tagged TLR4, which meant resveratrol obstructed TLR4 oligomerization upon LPS stimulation. Furthermore, resveratrol dose dependently inhibited the increase of STAT1, STAT3, and IκBα phosphorylation, as well as TNF-α and IL-6 secretion, induced by fibrillar Aβ. Therefore, resveratrol inhibited the microglial inflammatory responses triggered by both LPS and Aβ . Resveratrol was reported to exert a protective effect against cytotoxicity induced by Aβ25–35 or Aβ1–42 in cultured rat pheochromocytoma (PC12) cells. Resveratrol was also found to inhibit Aβ25–35 induced apoptotic cell death with the exhibition of morphological alterations and increase of TUNEL-positive cells. In this study, resveratrol was indicated to inhibit the Aβ25–35-induced dissipation of the mitochondrial membrane potential and intracellular ROI accumulation. Moreover, resveratrol was reported to influence the Aβ25–35-induced apoptotic signaling pathway, including preventing the cleavage of PARP, rescuing the decrease of Bcl-XL expression, inhibiting the expression of the proapoptotic Bax protein, blocking the activation of JNK via phosphorylation, and suppressing the increase of NF-κB DNA binding . It was also found in rat PC12 cells that resveratrol remodels Aβ soluble oligomers and fibrillar conformers into large nontoxic aggregates in a dose-dependent manner . Melatonin (N-acetyl-5-methoxy-tryptamine, MEL) was reported to be one of the potential candidates involved in antioxidant and neuroprotection in AD. In cultured murine HT22 hippocampal cells and primary hippocampal neuron cells, cotreatment with MEL and resveratrol was more effective in preventing Aβ1–42-induced neurotoxicity. MEL and resveratrol inhibited the activation of ERK, reduced ROS production, rescued glutathione (GSH) levels, and attenuated neuronal cell death. The Aβ1–42-induced increase of GSK3β activity and activation of AMPK were inhibited by either MEL or resveratrol alone, and cotreatment of these two compounds exerted a synergistic effect .
Other than these rat cells as in vitro models, there are many human cell lines applied to investigate the protective effects of resveratrol in AD (Table 2). For example, HEK293 cell, a specific cell line originally derived from human embryonic kidney cells grown in tissue culture, transfected with human APP695 was used to find the efficacy of resveratrol on Aβ clearance. The research found resveratrol had no effect on α-, β-, or γ-secretase-mediated cleavages of APP, which meant resveratrol did not influence the APP metabolism and Aβ production. Resveratrol did not facilitate Aβ degradation by neutral endopeptidase (NEP), endothelin-converting enzyme- (ECE-) 1 and ECE-2, or insulin-degrading enzyme (IDE) in HEK293 cells but promoted a proteasome-dependent intracellular clearance of Aβ without increasing total proteasome activity . In addition to its own antioxidant effect, resveratrol also regulated the gene expression of prooxidative and antioxidative enzymes in human umbilical vein endothelial cells (HUVEC). In HUVEC-derived EA.hy926 cells, resveratrol was found to decrease the expression of the ROS-producing enzyme Nox4 but increase the expression of ROS-inactivating enzymes, SOD1 and GPx1. By these results, resveratrol displayed a novel approach to reduce endothelial oxidative stress . Resveratrol could directly bind to both monomeric and fibrillar amyloid structures in human hippocampus slice, so resveratrol could directly stain Aβ plaques . SH-SY5Y neuroblastoma cells were applied to investigate the inhibitory function of resveratrol on beta-amyloid oligomeric cytotoxicity. It was indicated that resveratrol played protective roles in AD through suppressing the extension of amyloidogenic Aβ peptides and disaggregating Aβ42 fibrils but not inhibiting Aβ42 oligomer formation . SH-SY5Y human neuroblastoma cell cultures treated with Aβ complexes in presence or absence of resveratrol were applied to find the roles of resveratrol in Aβ metabolism. It was indicated that resveratrol had no direct antiamyloidogenic and fibril-destibilizing effects but mainly played a scavenging role through its neuroprotective activity against Aβ as well as Aβ-metal complexes. Resveratrol, a ROS scavenger, reduced the generations of Aβ-Fe, Aβ-Cu, and Aβ-Zn and thus reduced their toxicity. However, resveratrol was not sufficient to fully block Aβ-Al and Aβ-Cu toxicity because of the possibly different pathways, which were not only oxidative stress dependent . Studies are performed to investigate the effect of resveratrol on the production of prostanoids induced by IL-1β in SK-N-SH cells, a human neuroblastoma cell line. It was demonstrated that PGE2 and PGD2 production was drastically reduced by resveratrol, even at very low doses. However, the same dose of resveratrol did not greatly reduce mPGES-1 and COX-2 immunoreactivities, as well as COX-1. That was to say resveratrol reduced prostanoid synthesis and free radical generation without interfering with the expression of COX-1, COX-2, or mPGES-1 but via the reduction of COX-2 activity . Another study was carried out to find the role of resveratrol in preventing cell death due to oxidative stress in SK-N-BE, another neuroblastoma cell line. Resveratrol exerted antioxidant effects against H2O2 and 6-OHDA, and the neuroprotective mechanism was sensitive to sirtinol, indicating an involvement of SIRT1 enzymatic activation. Resveratrol inhibited the toxicity induced by TAT-α-syn (A30P) protein aggregation and Aβ42 fibrils, both increasing ROS production. In addition, resveratrol SIRT1 independently reduced Aβ42 toxicity, influenced Aβ42 fibril production and steadiness, and reduced intracellular Aβ42-dependent ROS generation . Although resveratrol is a potent activator of SIRT1 and the metabolic functions are chiefly through the deacetylase activity of SIRT1, resveratrol can also play a neuroprotective role by activating AMPK independently of SIRT1. Resveratrol reduced Aβ accumulation by activating AMPK signaling in HEK293 (APP-HEK293) and N2a (APP-N2a) cell lines and in primary neuronal cultures. Resveratrol activated AMPK via increasing cytosolic calcium levels and expediting CaMKKβ-dependent phosphorylation. Resveratrol reduced Aβ aggregation by activating autophagy and by promoting the lysosomal degradation of Aβ .
5. Resveratrol as a Therapeutic Agent for Other Neurodegenerative Diseases
Because of the neuroprotective effects of resveratrol mentioned above, the polyphenol has been found to play an important role in neurodegenerative diseases other than Alzheimer’s disease, for example, Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). The beneficial effects of resveratrol are not only antioxidant and anti-inflammatory actions but also activation of SIRT1 and vitagenes, which can prevent the deleterious effects triggered by oxidative stress. Recently, researches showed that resveratrol may offer a promising approach for treatment of these neurodegenerative disorders.
PD is a neuronal degeneration of dopaminergic neurons located in substantia nigra pars compacta (SNpc) and the PD patients often show increasing muscle rigidity, resting tremors, bradykinesia, and, in extreme cases, a nearly complete loss of movement. Ferretta et al. performed an in vitro experiment to find the effect of resveratrol treatment on primary fibroblast cultures from two patients with early-onset PD linked to different Park2 mutations. The results showed that resveratrol regulates energy homeostasis via activation of AMPK and SIRT1 and increase in mRNA expression of a number of PGC-1α’s target genes resulting in increased mitochondrial oxidative function . Lin et al. use an in vitro rotenone-induced PD model to verify the neuroprotective effects of resveratrol. Resveratrol acted in a neuroprotective manner to increase both HO-1 expression and autophagic flux with no effect on cell viability. Moreover, the effects of a pharmacological inducer of HO-1 were similar to those of resveratrol and protected against rotenone-induced cell death . In the study of Khan et al., male Wistar rats were used to make 6-OHDA-induced PD rat model, which were pretreated with resveratrol and subjected to unilateral intrastriatal injection of 6-OHDA. As a consequence, resveratrol was found to decrease the level of thiobarbituric acid reactive substances (TBARS), upregulate the antioxidant status, and lower the dopamine loss. In addition, resveratrol has been found to suppress COX-2 expression . Another research by Lofrumento et al. was performed to analyze the neuroprotective effects of resveratrol in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP-) induced PD mouse model. Results showed that resveratrol mitigated glial activation and decreased the levels of IL-1β, IL-6, and TNF-α, as well as their respective receptors in the SNpc of MPTP-treated mice . Furthermore, it was reported that inhibition of AMPK caused suppression of SIRT1 activity and reduced protective effects of resveratrol on rotenone-induced apoptosis, which meant AMPK-SIRT1-autophagy pathway played an important role in the neuroprotection by resveratrol on PD cellular models . These findings suggest that the resveratrol is an attractive alternative in the treatment of PD.
ALS is an adult onset, incurable fatal neurodegenerative disease, characterized by the selective loss of motor neurons in brain, brainstem, and spinal cord. Song et al. used SOD1 (G93A) transgenic mice, a classic animal model of ALS, to test the neuroprotective effects of resveratrol. In this research, resveratrol was found to regulate the expression of Sirt1 and PGC1-α and improve the lipid peroxidation, inhibiting p53 and its downstream apoptotic pathway. As a result, resveratrol significantly delayed the disease onset, extended the lifespan in the mice, ameliorated motor neuron loss, and alleviated the atrophy and mitochondrial dysfunction in the muscle fibers. That is to say the antioxidant and antiapoptotic effects of resveratrol are the major beneficial roles against ALS . Another research by Mancuso et al., also about the effects of resveratrol in SOD1 (G93A) ALS mice, showed that the protective effects of resveratrol were associated with increased expression and activation of sirtuin 1 and AMPK in the ventral spinal cord. Both mediators improved normalization of the autophagic flux and, more importantly, increased mitochondrial biogenesis in the SOD1 (G93A) spinal cord . Similar study carried out by Wang et al. proved the upregulation of the expression of SIRT1, which protected the ALS cell model from mutant SOD1-mediated toxicity . All of the studies represented a potential therapeutic target for preventing the motor neuron degeneration in ALS patients.
6. Poor Bioavailability of Resveratrol and Potential Solutions
In spite of the high bioactivity of resveratrol, we are still puzzled by its low bioavailability. As we mentioned before, resveratrol plays a very important role in Alzheimer’s disease, especially in vitro. However, it is difficult to show the same effects when expanded to in vivo animal models and human clinical trials. To date, there have been different results about the anti-inflammatory properties of resveratrol, among which some conclusions seemed to be conflicting or controversial. Because of the poor bioavailability of resveratrol, the concentrations of resveratrol at target tissues and cells appear far from sufficient to demonstrate efficacy in humans. Studies have shown that the oral absorption of resveratrol appeared to be at least 75%; however the bioavailability was poor on account of the rapid and extensive metabolism . Resveratrol, whose half-life is only 8–14 minutes, has been found to be quickly metabolized into sulfate and glucuronide metabolites in liver and intestinal epithelial cells in human [70, 71]. The poor bioavailability of resveratrol is also associated with the poor aqueous solubility, which is reported as <1 mg/mL . Additionally, trans-resveratrol is photosensitive, is easily oxidized, and presents unfavorable pharmacokinetics . Therefore, successful clinical application of resveratrol is a severe challenge for the medical as well as pharmaceutical technology. Researchers have tried different approaches to improve the solubility and bioavailability, including coadministration of inhibitors of trans-resveratrol metabolism, searching for analogs and elaboration of new trans-resveratrol delivery systems .
In recent years, a number of researches have focused on novel formulation approaches to stabilize and preserve resveratrol from degradation and increase its solubility so as to improve its bioavailability, to achieve a sustained release, and ultimately to transport resveratrol to specific locations via multiparticulate forms and colloidal carriers. Methylated resveratrol analogs exert similar biological activities that are comparable with those of the resveratrol. However, the methylated resveratrol analogs manifest better bioavailability as they are more easily transported into the cell and more resistant to degradation. Kang et al. firstly reported an artificial biosynthetic pathway to obtain methylated resveratrol compounds in the E. coli culture joined with resveratrol biosynthetic genes and two resveratrol O-methyltransferase genes . Amiot et al. developed an innovative soluble galenic form, which consisted of natural trans-resveratrol powder (40 mg) dissolved in a complex mixture containing polysorbate 20 and polyglyceryl-3-dioleate. Consequently, the novel formulation significantly improved the oral absorption of trans-resveratrol and the total trans-resveratrol bioavailability (+780%). A single dose in two lipid caplets (40 mg) of soluble trans-resveratrol was capable to enhance trans-resveratrol plasma concentrations around 10-fold, compared to the dry powder form . Amri et al. applied monodisperse functionalized porous polymeric microspheres for the sake of the stabilization and preservation of resveratrol . As another formulation, the complexation of trans-resveratrol with β-cyclodextrin (β-CD), hydroxypropyl-β-CD (HP-β-CD), randomly methylated-β-cyclodextrin (RM-β-CD), and maltosyl-β-cyclodextrin (G2-β-CD) has been investigated to increase trans-resveratrol solubility. On the other hand, either multiparticulate forms in the millimeter to micrometer range or colloidal carriers in the nanometer range have been used in several studies as the formulations to achieve targeted and/or sustained release of resveratrol. Das et al. found that Ca-pectinate beads and Zn-pectinate beads could encapsulate a large amount of resveratrol (>97.5%) and could be used for delayed release and site-specific delivery to the lower gastrointestinal tract [77, 78]. In the research of Frozza et al., trans-resveratrol was loaded into lipid-core nanocapsules. As a result, trans-resveratrol-loaded lipid-core nanocapsules increased the concentration of trans-resveratrol in the brain tissue and gastrointestinal safety was improved when compared with free trans-resveratrol .
Microparticulate systems may be a good choice to control the release and improve bioavailability of resveratrol. Recently, researchers incorporated resveratrol into cross-linked chitosan microspheres by vanillin to improve the stabilization, and the encapsulation efficiency of resveratrol in microspheres was up to 93.68% . In another study, microparticles were produced by crosslinking pectin molecules with zinc ions and with glutaraldehyde as hardening agent for pectins, as a specific delivery to colon with >94% encapsulation efficiency . Cyclodextrins can solubilize hydrophobic drugs in pharmaceutical applications and crosslink to form polymers used for drug delivery. By means of the transformation of crystalline cyclodextrins into amorphous mixtures of isomeric derivatives, the bioavailability of poorly soluble drugs, including resveratrol, can be improved and the aqueous solubility enhanced. In a research of resveratrol in human trial, the antioxidant effect was enhanced by treatment with the β-cyclodextrin- (βCD-) containing formulation compared to formulation containing trans-resveratrol alone . Resveratrol nanosuspensions were performed by high pressure homogenization and the stable nanosuspensions resulted in the enhancement of solubility of the drug improving its overall bioavailability . Solid lipid nanoparticles (SLN) may be an alternative which were used as a carrier for resveratrol in many studies. Resveratrol solubility, stability, and intracellular delivery were all increased by loading into SLN . In the study of Jose et al., resveratrol-loaded SLN were equally effective as free resveratrol and SLN could remarkably increase the brain concentration of resveratrol as compared to free resveratrol. Therefore the results showed that the resveratrol-loaded SLN serve as promising therapeutic systems in brain tissue .
Another novel method to deliver encapsulated drug is vesicular system, which means the colloidal particles containing concentric bilayer, capable of transporting both hydrophilic and hydrophobic drugs. Vesicular systems could increase bioavailability and provide therapeutic activity for a longer duration, including liposomes, transferosomes, phytosomes, and ethosomes. In a study, liposome formulations were chosen to optimize the loading of the rigid hydrophobic resveratrol and the liposomes showed the protection of resveratrol against biological degradation and metabolism thus improving the drug bioavailability . Liposomal resveratrol formulations designed for intravenous administration have also shown interesting properties . Different surfactants and lipids were used for the preparation of transferosomes and ethosomes and were characterized for size, zeta potential, stability, and permeation. Pangeni et al. used Span 60 and Span 80 to prepare resveratrol-loaded niosomes. As a result, the latter seemed to be more stable with narrow particle size distribution and high entrapment efficiency proving the improvement in bioavailability . Nanosponges are emerging nanohorizon in drug delivery through nanotechnology. Owing to their small size and porous nature they can combine with poorly soluble resveratrol within the matrix and improve the bioavailability . Encapsulating resveratrol in β-CD nanosponges improved its solubility in water and researchers believed that resveratrol-loaded nanosponges were viable for oral and topical delivery systems . In a recent study, Pund and his colleagues formulated a lipid-based delivery system of resveratrol with self-nanoemulsifying ability, containing Acrysol K 150 as a lipid and mixture of Labrasol and Transcutol HP as the surfactant system. As a result, lipid based nanoemulsifying resveratrol enhanced solubility in vitro and therapeutic efficacy in vivo .
7. Clinical Researches of Resveratrol in AD
There is growing evidence that resveratrol may benefit in AD treatment, both in vitro and in vivo. However, there is not a complete large-scale clinical trial coming to a conclusion until now. Resveratrol seems to be well tolerated and no marked toxicity was reported. Bioavailability of resveratrol is one of the focal points because the compound is poorly bioavailable, low water soluble, and chemically unstable [69, 90]. After oral administration or intravenous injection of resveratrol in humans, resveratrol was rapidly metabolized within 2 hours, even a peak in 30 minutes . Several studies in vivo in animals and humans demonstrated a very low intestinal uptake of resveratrol, and it was difficult to detect unmetabolized resveratrol in the circulating plasma . It was indicated that trans-resveratrol pharmacokinetics following oral administration of 200 mg thrice daily was independent of age. However, the plasma concentrations of trans-resveratrol were relatively low . Although in vivo evidence is emerging in animal models that resveratrol is bioavailable and bioactive , conclusive results in human trials are still lacking. In recent years many researchers have tried a variety of ways to find the effective administration methods of resveratrol [74, 92–94], but none of them is fully satisfied. As selective ways, some researches put emphasis up on the resveratrol metabolites responsible for its biological activity and the analogs with similar neuroprotective properties .
There are currently numerous clinical trials to investigate the effects of resveratrol on neurodegenerative diseases, of course including AD, in spite of the enormous difficulties . In a double-blind, placebo-controlled, crossover investigation on healthy young volunteers consuming 500 mg resveratrol, levels of total hemoglobin were remarkably higher in the frontal cortex during task performance . However, cognitive performance was not affected [29, 96]. In a randomized controlled trial (RCT) versus placebo, 60 AD patients were given liquid resveratrol with glucose and malate as a dietary supplement delivered in grape juice. The ADAS-cog scores were assessed at regular intervals up to 1 year after study commencement [96, 97]. In another multi-interventional clinical trial in mild cognitive impairment (MCI), resveratrol supplementation or caloric restriction or omega-3 supplementation or placebo was provided for 6 months, and then the ADAS-cog scores would be assessed .
Resveratrol is a novel agent for treatment of AD because of its multiple mechanisms in neuroprotection. As the treatment of AD is still a worldwide problem, therapeutic potential of resveratrol has attracted the interest of researchers to shift emphasis on. Plenty of trials have been exerted to find the concrete details of the neuroprotective mechanisms of resveratrol in cell cultures and animal models of AD. For the antioxidative and anti-inflammatory functions, resveratrol truly represents the beneficial effects on AD. Furthermore, some official systematic clinical trials about resveratrol treatment in AD have also been underway. Although the difficulties of clinical application are enormous, such as the bioavailability, dosage, and side effects, scientists are still trying to seek out the detailed mechanism and the suitable clinical administration of resveratrol.
Conflict of Interests
The authors declare that there is no conflict of interests regarding the publication of this paper.
This work was supported by grants from the National Natural Science Foundation of China (81000544, 81171209, and 81371406) and Shandong Provincial Natural Science Foundation, China (ZR2010HQ004 and ZR2011HZ001).
- D. J. Selkoe, “Alzheimer's disease: genes, proteins, and therapy,” Physiological Reviews, vol. 81, no. 2, pp. 741–766, 2001.
- A. Granzotto and P. Zatta, “Resveratrol acts not through Anti-Aggregative pathways but mainly via its scavenging properties against Aβ and Aβ-metal complexes toxicity,” PLoS ONE, vol. 6, no. 6, Article ID e21565, 2011.
- K. Yaffe, “Treatment of Alzheimer disease and prognosis of dementia: time to translate research to results,” JAMA—Journal of the American Medical Association, vol. 304, no. 17, pp. 1952–1953, 2010.
- H. Allain, D. Bentué-Ferrer, O. Tribut, S. Gauthier, B.-F. Michel, and C. D.-L. Rochelle, “Alzheimer's disease: the pharmacological pathway,” Fundamental and Clinical Pharmacology, vol. 17, no. 4, pp. 419–428, 2003.
- J. Kim, H. J. Lee, and K. W. Lee, “Naturally occurring phytochemicals for the prevention of Alzheimer's disease,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1415–1430, 2010.
- F. Li, Q. Gong, H. Dong, and J. Shi, “Resveratrol, a neuroprotective supplement for Alzheimer's disease,” Current Pharmaceutical Design, vol. 18, no. 1, pp. 27–33, 2012.
- J. Ferrières, “The French paradox: lessons for other countries,” Heart, vol. 90, no. 1, pp. 107–111, 2004.
- J. A. Baur and D. A. Sinclair, “Therapeutic potential of resveratrol: the in vivo evidence,” Nature Reviews Drug Discovery, vol. 5, no. 6, pp. 493–506, 2006.
- P. Saiko, A. Szakmary, W. Jaeger, and T. Szekeres, “Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad?” Mutation Research—Reviews in Mutation Research, vol. 658, no. 1-2, pp. 68–94, 2008.
- C. A. Oomen, E. Farkas, V. Roman, E. M. van der Beek, P. G. M. Luiten, and P. Meerlo, “Resveratrol preserves cerebrovascular density and cognitive function in aging mice,” Frontiers in Aging Neuroscience, vol. 1, p. 4, 2009.
- D. P. Perl, “Neuropathology of Alzheimer's disease,” Mount Sinai Journal of Medicine, vol. 77, no. 1, pp. 32–42, 2010.
- J. Hardy, “Alzheimer's disease: the amyloid cascade hypothesis—an update and reappraisal,” Journal of Alzheimer's Disease, vol. 9, no. 3 supplement, pp. 151–153, 2006.
- E. D. Roberson and L. Mucke, “100 Years and counting: prospects for defeating Alzheimer's disease,” Science, vol. 314, no. 5800, pp. 781–784, 2006.
- A. Nunomura, “Oxidative stress hypothesis for Alzheimer's disease and its potential therapeutic implications,” Rinsho Shinkeigaku, vol. 53, no. 11, pp. 1043–1045, 2013.
- A. A. Abolfathi, D. Mohajeri, A. Rezaie, and M. Nazeri, “Protective effects of green tea extract against hepatic tissue injury in streptozotocin-induced diabetic rats,” Evidence-based Complementary and Alternative Medicine, vol. 2012, Article ID 740671, 10 pages, 2012.
- M. T. Heneka and M. K. O'Banion, “Inflammatory processes in Alzheimer's disease,” Journal of Neuroimmunology, vol. 184, no. 1-2, pp. 69–91, 2007.
- H. Capiralla, V. Vingtdeux, H. Zhao et al., “Resveratrol mitigates lipopolysaccharide- and Aβ-mediated microglial inflammation by inhibiting the TLR4/NF-κB/STAT signaling cascade,” Journal of Neurochemistry, vol. 120, no. 3, pp. 461–472, 2012.
- C. Velez-Pardo, G. Garcia Ospina, and M. Jimenez del Rio, “Aβ[25-35] peptide and iron promote apoptosis in lymphocytes by an oxidative stress mechanism: involvement of H2O2, caspase-3, NF-κB, p53 and c-Jun,” NeuroToxicology, vol. 23, no. 3, pp. 351–365, 2002.
- M. G. Tansey, M. K. McCoy, and T. C. Frank-Cannon, “Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic intervention,” Experimental Neurology, vol. 208, no. 1, pp. 1–25, 2007.
- Y. Liu, L. Qin, B. C. Wilson, L. An, J.-S. Hong, and B. Liu, “Inhibition by naloxone stereoisomers of β-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons,” Journal of Pharmacology and Experimental Therapeutics, vol. 302, no. 3, pp. 1212–1219, 2002.
- O. B. Villaflores, Y.-J. Chen, C.-P. Chen, J.-M. Yeh, and T.-Y. Wu, “Curcuminoids and resveratrol as anti-Alzheimer agents,” Taiwanese Journal of Obstetrics and Gynecology, vol. 51, no. 4, pp. 515–525, 2012.
- A. del C. Alonso, T. Zaidi, M. Novak, I. Grundke-Iqbal, and K. Iqbal, “Hyperphosphorylation induces self-assembly of into tangles of paired helical filaments/straight filaments,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 12, pp. 6923–6928, 2001.
- A. D. C. Alonso, B. Li, I. Grundke-Iqbal, and K. Iqbal, “Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies,” Current Alzheimer Research, vol. 5, no. 4, pp. 375–384, 2008.
- K. Iqbal, F. Liu, C.-X. Gong, and I. Grundke-Iqbal, “Tau in Alzheimer disease and related tauopathies,” Current Alzheimer research, vol. 7, no. 8, pp. 656–664, 2010.
- D. M. Wilcock, N. Gharkholonarehe, W. E. van Nostrand, J. Davis, M. P. Vitek, and C. A. Colton, “Amyloid reduction by amyloid-β vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease,” Journal of Neuroscience, vol. 29, no. 25, pp. 7957–7965, 2009.
- D. M. Holtzman, “Alzheimer's disease: moving towards a vaccine,” Nature, vol. 454, no. 7203, pp. 418–420, 2008.
- G. R. Mallucci, M. D. White, M. Farmer et al., “Targeting cellular prion protein reverses early cognitive deficits and neurophysiological dysfunction in prion-infected mice,” Neuron, vol. 53, no. 3, pp. 325–335, 2007.
- D. J. Selkoe, “Alzheimer's disease is a synaptic failure,” Science, vol. 298, no. 5594, pp. 789–791, 2002.
- G. M. Pasinetti, J. Wang, P. Marambaud et al., “Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders,” Experimental Neurology, vol. 232, no. 1, pp. 1–6, 2011.
- J. Wang, L. Ho, Z. Zhao et al., “Moderate consumption of Cabernet Sauvignon attenuates Aβ neuropathology in a mouse model of Alzheimer's disease,” The FASEB Journal, vol. 20, no. 13, pp. 2313–2320, 2006.
- J. P. Cleary, D. M. Walsh, J. J. Hofmeister et al., “Natural oligomers of the amyloid-β protein specifically disrupt cognitive function,” Nature Neuroscience, vol. 8, no. 1, pp. 79–84, 2005.
- J. Wang, L. Ho, W. Zhao et al., “Grape-derived polyphenolics prevent Aβ oligomerization and attenuate cognitive deterioration in a mouse model of Alzheimer's disease,” Journal of Neuroscience, vol. 28, no. 25, pp. 6388–6392, 2008.
- B. T. Jeon, E. A. Jeong, H. J. Shin et al., “Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet,” Diabetes, vol. 61, no. 6, pp. 1444–1454, 2012.
- M. Lagouge, C. Argmann, Z. Gerhart-Hines et al., “Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α,” Cell, vol. 127, no. 6, pp. 1109–1122, 2006.
- B. Dasgupta and J. Milbrandt, “Resveratrol stimulates AMP kinase activity in neurons,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 17, pp. 7217–7222, 2007.
- M. Sharma and Y. K. Gupta, “Chronic treatment with trans resveratrol prevents intracerebroventricular streptozotocin induced cognitive impairment and oxidative stress in rats,” Life Sciences, vol. 71, no. 21, pp. 2489–2498, 2002.
- A. Kumar, P. S. Naidu, N. Seghal, and S. S. V. Padi, “Neuroprotective effects of resveratrol against intracerebroventricular colchicine-induced cognitive impairment and oxidative stress in rats,” Pharmacology, vol. 79, no. 1, pp. 17–26, 2007.
- R. Schmatz, C. M. Mazzanti, R. Spanevello et al., “Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 610, no. 1–3, pp. 42–48, 2009.
- M. Rahvar, M. Nikseresht, S. M. Shafiee et al., “Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain,” Neurochemical Research, vol. 36, no. 5, pp. 761–765, 2011.
- D. Kim, M. D. Nguyen, M. M. Dobbin et al., “SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis,” The EMBO Journal, vol. 26, no. 13, pp. 3169–3179, 2007.
- E. O. Lee, H. J. Park, J. L. Kang, H.-S. Kim, and Y. H. Chong, “Resveratrol reduces glutamate-mediated monocyte chemotactic protein-1 expression via inhibition of extracellular signal-regulated kinase 1/2 pathway in rat hippocampal slice cultures,” Journal of Neurochemistry, vol. 112, no. 6, pp. 1477–1487, 2010.
- Y. B. Ju, O. C. Soon, S.-H. Choi et al., “Neuroprotective effect of Smilacis chinae rhizome on NMDA-induced neurotoxicity in vitro and focal cerebral ischemia in vivo,” Journal of Pharmacological Sciences, vol. 106, no. 1, pp. 68–77, 2008.
- Y. S. Han, W. H. Zheng, S. Bastianetto, J. G. Chabot, and R. Quirion, “Neuroprotective effects of resveratrol against β-amyloid-induced neurotoxicity in rat hippocampal neurons: Involvement of protein kinase C,” British Journal of Pharmacology, vol. 141, no. 6, pp. 997–1005, 2004.
- S. Bastianetto, W.-H. Zheng, and R. Quirion, “Neuroprotective abilities of resveratrol and other red wine constituents against nitric oxide-related toxicity in cultured hippocampal neurons,” British Journal of Pharmacology, vol. 131, no. 4, pp. 711–720, 2000.
- E. Candelario-Jalil, A. C. P. de Oliveira, S. Gräf et al., “Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia,” Journal of Neuroinflammation, vol. 4, article 25, 2007.
- Y. A. Kim, S.-Y. Lim, S.-H. Rhee et al., “Resveratrol inhibits inducible nitric oxide synthase and cyclooxygenase-2 expression in β-amyloid-treated C6 glioma cells,” International Journal of Molecular Medicine, vol. 17, no. 6, pp. 1069–1075, 2006.
- J.-H. Jang and Y.-J. Surh, “Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death,” Free Radical Biology and Medicine, vol. 34, no. 8, pp. 1100–1110, 2003.
- A. R. Ladiwala, J. C. Lin, S. S. Bale et al., “Resveratrol selectively remodels soluble oligomers and fibrils of amyloid Aβ into off-pathway conformers,” Journal of Biological Chemistry, vol. 285, no. 31, pp. 24228–24237, 2010.
- K. J. Kwon, H.-J. Kim, C. Y. Shin, and S.-H. Han, “Melatonin potentiates the neuroprotective properties of resveratrol against beta-amyloid-induced neurodegeneration by modulating AMP-activated protein Kinase pathways,” Journal of Clinical Neurology, vol. 6, no. 3, pp. 127–137, 2010.
- P. Marambaud, H. Zhao, and P. Davies, “Resveratrol promotes clearance of Alzheimer's disease amyloid-β peptides,” The Journal of Biological Chemistry, vol. 280, no. 45, pp. 37377–37382, 2005.
- G. Spanier, H. Xu, N. Xia et al., “Resveratrol reduces endothelial oxidative stress by modulating the gene expression of superoxide dismutase 1 (SOD1), glutathione peroxidase 1 (GPx1) and NADPH oxidase subunit (Nox4),” Journal of Physiology and Pharmacology, vol. 60, pp. 111–116, 2009.
- Y. Feng, X. P. Wang, S. G. Yang et al., “Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation,” Neurotoxicology, vol. 30, no. 6, pp. 986–995, 2009.
- L. Wendeburg, A. C. P. de Oliveira, H. S. Bhatia, E. Candelario-Jalil, and B. L. Fiebich, “Resveratrol inhibits prostaglandin formation in IL-1β-stimulated SK-N-SH neuronal cells,” Journal of Neuroinflammation, vol. 6, article 26, 2009.
- D. Albani, L. Polito, S. Batelli et al., “The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by α-synuclein or amyloid-β (1-42) peptide,” Journal of Neurochemistry, vol. 110, no. 5, pp. 1445–1456, 2009.
- V. Vingtdeux, L. Giliberto, H. Zhao et al., “AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-β peptide metabolism,” The Journal of Biological Chemistry, vol. 285, no. 12, pp. 9100–9113, 2010.
- D. J. Bonda, H.-G. Lee, A. Camins et al., “The sirtuin pathway in ageing and Alzheimer disease: mechanistic and therapeutic considerations,” The Lancet Neurology, vol. 10, no. 3, pp. 275–279, 2011.
- D. Beher, J. Wu, S. Cumine et al., “Resveratrol is not a direct activator of sirt1 enzyme activity,” Chemical Biology and Drug Design, vol. 74, no. 6, pp. 619–624, 2009.
- F. Zhang, J. Liu, and J.-S. Shi, “Anti-inflammatory activities of resveratrol in the brain: role of resveratrol in microglial activation,” European Journal of Pharmacology, vol. 636, no. 1–3, pp. 1–7, 2010.
- P. Kumar, S. S. V. Padi, P. S. Naidu, and A. Kumar, “Effect of resveratrol on 3-nitropropionic acid-induced biochemical and behavioural changes: possible neuroprotective mechanisms,” Behavioural Pharmacology, vol. 17, no. 5-6, pp. 485–492, 2006.
- J.-F. Ge, J.-P. Qiao, C.-C. Qi, C.-W. Wang, and J.-N. Zhou, “The binding of resveratrol to monomer and fibril amyloid beta,” Neurochemistry International, vol. 61, no. 7, pp. 1192–1201, 2012.
- A. Ferretta, A. Gaballo, P. Tanzarella et al., “Effect of resveratrol on mitochondrial function: Implications in parkin-associated familiar Parkinson's disease,” Biochimica et Biophysica Acta: Molecular Basis of Disease, vol. 1842, no. 7, pp. 902–915, 2014.
- T.-K. Lin, S.-D. Chen, Y.-C. Chuang et al., “Resveratrol partially prevents rotenone-induced neurotoxicity in dopaminergic SH-SY5Y cells through induction of heme oxygenase-1 dependent autophagy,” International Journal of Molecular Sciences, vol. 15, no. 1, pp. 1625–1646, 2014.
- M. M. Khan, A. Ahmad, T. Ishrat et al., “Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease,” Brain Research, vol. 1328, pp. 139–151, 2010.
- D. D. Lofrumento, G. Nicolardi, A. Cianciulli et al., “Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: possible role of SOCS-1 in reducing pro-inflammatory responses,” Innate Immunity, vol. 20, no. 3, pp. 249–260, 2014.
- Y. Wu, X. Li, J. X. Zhu et al., “Resveratrol-activated AMPK/SIRT1/autophagy in cellular models of Parkinson's disease,” NeuroSignals, vol. 19, no. 3, pp. 163–174, 2011.
- L. Song, L. Chen, X. Zhang, J. Li, and W. Le, “Resveratrol ameliorates motor neuron degeneration and improves survival in mouse model of amyotrophic lateral sclerosis,” BioMed Research International, vol. 2014, Article ID 483501, 10 pages, 2014.
- R. Mancuso, J. del Valle, L. Modol et al., “Resveratrol improves motoneuron function and extends survival in SOD1G93A ALS mice,” Neurotherapeutics, vol. 11, no. 2, pp. 419–432, 2014.
- J. Wang, Y. Zhang, L. Tang, N. Zhang, and D. Fan, “Protective effects of resveratrol through the up-regulation of SIRT1 expression in the mutant hSOD1-G93A-bearing motor neuron-like cell culture model of amyotrophic lateral sclerosis,” Neuroscience Letters, vol. 503, no. 3, pp. 250–255, 2011.
- T. Walle, “Bioavailability of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 9–15, 2011.
- V. Ponzo, L. Soldati, and S. Bo, “Resveratrol: a supplementation for men or for mice?” Acta Veterinaria Scandinavica, vol. 12, article 158, 2014.
- T. S. Anekonda, “Resveratrol—a boon for treating Alzheimer's disease?” Brain Research Reviews, vol. 52, no. 2, pp. 316–326, 2006.
- J. M. López-Nicolás and F. García-Carmona, “Aggregation state and pKa values of (E)-resveratrol as determined by fluorescence spectroscopy and UV-visible absorption,” Journal of Agricultural and Food Chemistry, vol. 56, no. 17, pp. 7600–7605, 2008.
- R. L. Frozza, A. Bernardi, K. Paese et al., “Characterization of trans-resveratrol-loaded lipid-core nanocapsules and tissue distribution studies in rats,” Journal of Biomedical Nanotechnology, vol. 6, no. 6, pp. 694–703, 2010.
- M. J. Amiot, B. Romier, T.-M. Anh Dao et al., “Optimization of trans-Resveratrol bioavailability for human therapy,” Biochimie, vol. 95, no. 6, pp. 1233–1238, 2013.
- S. Y. Kang, J. K. Lee, O. Choi et al., “Biosynthesis of methylated resveratrol analogs through the construction of an artificial biosynthetic pathway in E. coli,” BMC Biotechnology, vol. 14, no. 1, article 67, 2014.
- A. Amri, J. C. Chaumeil, S. Sfar, and C. Charrueau, “Administration of resveratrol: what formulation solutions to bioavailability limitations?” Journal of Controlled Release, vol. 158, no. 2, pp. 182–193, 2012.
- S. Das, K.-Y. Ng, and P. C. Ho, “Formulation and optimization of zinc-pectinate beads for the controlled delivery of resveratrol,” AAPS PharmSciTech, vol. 11, no. 2, pp. 729–742, 2010.
- S. Das and K.-Y. Ng, “Resveratrol-loaded calcium-pectinate beads: effects of formulation parameters on drug release and bead characteristics,” Journal of Pharmaceutical Sciences, vol. 99, no. 2, pp. 840–860, 2010.
- H. Peng, H. Xiong, J. Li et al., “Vanillin cross-linked chitosan microspheres for controlled release of resveratrol,” Food Chemistry, vol. 121, no. 1, pp. 23–28, 2010.
- S. Das, K. Y. Ng, and P. C. Ho, “Design of a pectin-based microparticle formulation using zinc ions as the cross-linking agent and glutaraldehyde as the hardening agent for colonic-specific delivery of resveratrol: in vitro and in vivo evaluations,” Journal of Drug Targeting, vol. 19, no. 6, pp. 446–457, 2011.
- J. R. Moyano-Mendez, G. Fabbrocini, D. de Stefano et al., “Enhanced antioxidant effect of trans-resveratrol: potential of binary systems with polyethylene glycol and cyclodextrin,” Drug Development and Industrial Pharmacy, vol. 40, no. 10, pp. 1300–1307, 2014.
- S. Kobierski, K. Ofori-Kwakye, R. H. Müller, and C. M. Keck, “Resveratrol nanosuspensions for dermal application—production, characterization, and physical stability,” Pharmazie, vol. 64, no. 11, pp. 741–747, 2009.
- K. Teskač and J. Kristl, “The evidence for solid lipid nanoparticles mediated cell uptake of resveratrol,” International Journal of Pharmaceutics, vol. 390, no. 1, pp. 61–69, 2010.
- S. Jose, S. S. Anju, T. A. Cinu, N. A. Aleykutty, S. Thomas, and E. B. Souto, “In vivo pharmacokinetics and biodistribution of resveratrol-loaded solid lipid nanoparticles for brain delivery,” International Journal of Pharmaceutics, vol. 474, no. 1-2, pp. 6–13, 2014.
- C. Bonechi, S. Martini, L. Ciani et al., “Using liposomes as carriers for polyphenolic compounds: the case of Trans-resveratrol,” PLoS ONE, vol. 7, no. 8, Article ID e41438, 2012.
- R. Pangeni, J. K. Sahni, J. Ali, S. Sharma, and S. Baboota, “Resveratrol: review on therapeutic potential and recent advances in drug delivery,” Expert Opinion on Drug Delivery, vol. 11, no. 8, pp. 1285–1298, 2014.
- R. Z. Ahmed, G. Patil, and Z. Zaheer, “Nanosponges—a completely new nano-horizon: pharmaceutical applications and recent advances,” Drug Development and Industrial Pharmacy, vol. 39, no. 9, pp. 1263–1272, 2013.
- K. A. Ansari, P. R. Vavia, F. Trotta, and R. Cavalli, “Cyclodextrin-based nanosponges for delivery of resveratrol: in vitro characterisation, stability, cytotoxicity and permeation study,” AAPS PharmSciTech, vol. 12, no. 1, pp. 279–286, 2011.
- S. Pund, R. Thakur, U. More, and A. Joshi, “Lipid based nanoemulsifying resveratrol for improved physicochemical characteristics, in vitro cytotoxicity and in vivo antiangiogenic efficacy,” Colloids and Surfaces B: Biointerfaces, vol. 120, pp. 110–117, 2014.
- C.-H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J.-L. Beaudeux, “Resveratrol bioavailability and toxicity in humans,” Molecular Nutrition and Food Research, vol. 54, no. 1, pp. 7–16, 2010.
- T. Nunes, L. Almeida, J.-F. Rocha et al., “Pharmacokinetics of trans-resveratrol following repeated administration in healthy elderly and young subjects,” Journal of Clinical Pharmacology, vol. 49, no. 12, pp. 1477–1482, 2009.
- M. Sessa, M. L. Balestrieri, G. Ferrari et al., “Bioavailability of encapsulated resveratrol into nanoemulsion-based delivery systems,” Food Chemistry, vol. 147, pp. 42–50, 2014.
- J. M. Planas, I. Alfaras, H. Colom, and M. E. Juan, “The bioavailability and distribution of trans-resveratrol are constrained by ABC transporters,” Archives of Biochemistry and Biophysics, vol. 527, no. 2, pp. 67–73, 2012.
- A. R. Neves, M. Lúcio, S. Martins, J. L. C. Lima, and S. Reis, “Novel resveratrol nanodelivery systems based on lipid nanoparticles to enhance its oral bioavailability,” International Journal of Nanomedicine, vol. 8, pp. 177–187, 2013.
- K. R. Patel, E. Scott, V. A. Brown, A. J. Gescher, W. P. Steward, and K. Brown, “Clinical trials of resveratrol,” Annals of the New York Academy of Sciences, vol. 1215, no. 1, pp. 161–169, 2011.
- D. O. Kennedy, E. L. Wightman, J. L. Reay et al., “Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation,” The American Journal of Clinical Nutrition, vol. 91, no. 6, pp. 1590–1597, 2010.
- P. Mecocci and M. C. Polidori, “Antioxidant clinical trials in mild cognitive impairment and Alzheimer's disease,” Biochimica et Biophysica Acta—Molecular Basis of Disease, vol. 1822, no. 5, pp. 631–638, 2012.
Copyright © 2014 Teng Ma et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.